UTAH, United States (CMC) — A molecular diagnostics company based in the United States, says it has strengthened relationships with key regional customers throughout the Caribbean basin to purchase Zika virus diagnostic.

Co-Diagnostics Inc, located in the state of Utah, says its potential customer base across the Caribbean includes laboratories, regional health ministries and hospitals interested in offering a state-of-the-art molecular diagnostic for the mosquito borne Zika virus to their patients.

“To date, representatives and future product distributors have conducted on-site suitability assessments at dozens of locations in countries across the region, with the understanding that these locations would be among the first to have access to the Zika virus test upon completion of successful performance evaluation and validation studies.”

Co-Diagnostics Inc is also an approved reseller of diagnostic equipment, to enable upgraded laboratory facilities for those locations who have not previously been able to offer molecular diagnostics.

“Molecular diagnostics are the internationally recognised gold standard in disease detection, and Co-Diagnostics’ assays are built on our own platform without expensive royalty payments built in to the cost. We are uniquely positioned to assist the many overlooked and underserved populations in this region interested in a competitively priced, high quality diagnostic tool to assist in the detection of the Zika virus,” said Dwight Egan, the CEO of Co-Diagnostics.

Earlier this year the World Health Organisation (WHO) urged Caribbean countries to continue to be vigilant although there has been a decline in case of the mosquito-borne Zika virus.